AKT1 and cancer: As mTOR is a key downstream effector of the PI3K/Akt pathway and plays a crucial role in cell growth and proliferation, its inhibition, such as by rapamycin, is often targeted in cancer therapy due to the pathway’s frequent dysregulation in tumors.